Amgen Halts Key Trials, But Weight Loss Bet Keeps It in Play

Forward-Looking Analysis

Wall Street consensus estimates project Amgen’s 2026Q2 earnings per share (EPS) to range between $5.00 and $5.08, with an average estimate of $5.04, according to data from February 4, 2026. Two analysts have contributed to this estimate, indicating a narrow spread in expectations. While specific revenue figures for Q2 2026 are not explicitly detailed in the provided consensus data, the full-year 2026 EPS guidance suggests a total of $19.75, with estimates ranging from $19.36 to $20.14. This implies a modest growth trajectory compared to the prior year, where trailing EPS stood at $7.55. Analysts anticipate earnings growth of approximately 3.73% over the next year, moving from $20.62 to $21.39 per share. The forward price-to-earnings ratio is currently estimated at 13.65, suggesting a valuation that may reflect cautious optimism amid broader market conditions. The company’s ability to meet the $5.04 EPS target will likely hinge on the sustained performance of its core therapeutic portfolio and successful execution of its pipeline strategies, including recent developments in weight loss drugs and oncology treatments.

Historical Performance Review

Amgen’s 2026Q1 results demonstrated robust financial momentum, generating $8.22 billion in revenue against a $5.87 billion gross profit. The company reported a net income of $1.82 billion, translating to an EPS of $3.37. These figures highlight strong operational efficiency and profitability in the first quarter, setting a solid baseline for the subsequent quarters. The significant gross margin indicates effective cost management and pricing power within its key therapeutic areas, positioning the company favorably for the remainder of the fiscal year.

Additional News

Amgen recently declared a $2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026, reinforcing its commitment to shareholder returns. The stock has seen mixed recent movements, closing at $387.42 with a -1.44% move, though it outperformed the S&P 500 in recent sessions. In pipeline developments, Amgen announced the halt of key Phase 3 trials for Bemarituzumab in gastric cancer and Rocatinlimab in dermatology, narrowing near-term upside in these specific areas. However, the company remains aggressive in the weight loss drug market, with multiple Phase 3 trials running for its monthly candidate, aiming to compete with Eli Lilly and Novo Nordisk. Additionally, Amgen’s Repatha expansion and broader portfolio growth continue to drive investor interest, with some analysts viewing the stock as a bargain based on cash flow metrics despite fair earnings pricing.

Summary & Outlook

Amgen exhibits strong financial health, supported by solid Q1 2026 performance and consistent dividend payouts. Growth catalysts include its expanding pipeline in weight loss and oncology, while risks involve halted clinical trials for Bemarituzumab and Rocatinlimab. Despite these setbacks, the company’s diversified portfolio and strong cash flow generation provide a buffer. We maintain a neutral-to-bullish stance, anticipating steady earnings growth driven by core brand performance, though investors should monitor pipeline updates closely for potential volatility. The current valuation offers a reasonable entry point for long-term investors seeking stability in the biotech sector.